Monitor for site activations in Q4 2026 and eventual enrollment updates. The trial's head-to-head design against durvalumab in a curative-intent setting could be a significant catalyst if positive data emerge, but no timeline for data readout was provided.
Drug in focus
SMMT drug pipeline →ivonescimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
- Time to market
- If approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
- Next catalyst
- None dated
What to watchThe November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 18 $10.50entry
- T+1 · 3d ago +0.67%α +2.63% · $10.57
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 25d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Summit Therapeutics announced the planned initiation of a global Phase III trial, HARMONi-10, evaluating ivonescimab versus durvalumab as consolidation therapy in unresectable Stage III non-small cell lung cancer. This is the company's sixth sponsored Phase III study of ivonescimab and expands its development program into the locally advanced, unresectable setting. No financial data or clinical results were disclosed.
Key Facts
- Summit announced the planned initiation of the global Phase III HARMONi-10 trial of ivonescimab.
- HARMONi-10 will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not progressed after platinum-based concurrent chemoradiation.
- Global clinical trial site activations are expected to begin in Q4 2026.
- HARMONi-10 is Summit's sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC.
- The primary endpoint is progression-free survival (PFS).
- Ivonescimab is not approved by any regulatory authority in Summit's license territories (including the US and Europe); it was approved in China in May 2024.
- Five Phase III ivonescimab trials have read out to date, all five with positive data.
Financial Impact
No financial figures disclosed; trial initiation does not have an immediate revenue impact.
Risk Factors
- Ivonescimab is not yet approved in Summit's license territories; regulatory and clinical risks remain.
- Phase III trials are expensive and may require additional capital; no financial guidance was provided.
- Competition from durvalumab and other PD-(L)1 inhibitors in the consolidation setting is established.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000094 |
| Document: a2026_prx111xxharmoni-10.htm | 0001599298-26-000094 |
| Document: 0001599298-26-000094-index-headers.html | 0001599298-26-000094 |
| Document: 0001599298-26-000094-index.html | 0001599298-26-000094 |
| Document: 0001599298-26-000094.txt | 0001599298-26-000094 |
Track record
24 reports on SMMT
8 of 13 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 18, 20263d ago 8-K Neutral 4/10 Viewing Entry $10.50 to $10.57 Now $9.95 −5.24% ▲ +0.67% +2.63% vs SPY
- Nov 16, 20266d ago 8-K Bearish 7/10 Entry $11.82 to $10.67 Now $9.95 +15.82% ▲ +9.73% +8.71% vs SPY
- Nov 4, 202617d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $9.95 −29.88% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202617d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $9.95 −29.88% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202617d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $9.95 −38.47% ▼ −12.24% −7.84% vs SPY
- Oct 21, 20264w ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $9.95 −37.14% ▼ −1.77% −0.59% vs SPY
- Oct 19, 20264w ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $9.95 −36.10% ▲ +3.34% +3.00% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $9.95 −39.29% ▲ +3.17% +3.38% vs SPY
- Sep 15, 20269w ago 8-K Bullish 7/10 Entry $17.40 to $17.54 Now $9.95 −42.82% ▲ +0.80% +0.48% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $18.42 to $17.40 Now $9.95 −45.98% ▼ −5.54% −5.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers